A Novel Stent Coated with Antibodies to Endoglin Inhibits Neointimal Formation of Porcine Coronary Arteries

Endoglin/CD105 is an accessory protein of the transforming growth factor-β receptor system that plays a critical role in proliferation of endothelial cells and neovasculature. Here, we aimed to assess the effect of novel stents coated with antibodies to endoglin (ENDs) on coronary neointima formatio...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2014-01, Vol.2014 (2014), p.1-7
Main Authors: Cui, Song, Liu, Jing-Hua, Song, Xian-Tao, Ma, Guo-Lin, Du, Ben-Jun, Lü, Shu-Zheng, Meng, Li-Jun, Gao, Quan-Sheng, Li, Kefeng
Format: Article
Language:English
Subjects:
Angioplasty
Animals
Antibodies - chemistry
Antibodies - immunology
Antigens, CD - chemistry
Antigens, CD - immunology
Coronary arteries
Coronary vessels
Coronary Vessels - pathology
Disease Models, Animal
Drug-Eluting Stents
Endoglin
Humans
Inflammation - pathology
Inflammation - therapy
Neointima - pathology
Neointima - therapy
Receptors, Cell Surface - chemistry
Receptors, Cell Surface - immunology
Stent (Surgery)
Stents
Swine
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endoglin/CD105 is an accessory protein of the transforming growth factor-β receptor system that plays a critical role in proliferation of endothelial cells and neovasculature. Here, we aimed to assess the effect of novel stents coated with antibodies to endoglin (ENDs) on coronary neointima formation. Thirty ENDs, thirty sirolimus-eluting stents (SESs), and thirty bare metal stents (BMSs) were randomly assigned and placed in the coronary arteries in 30 juvenile pigs. Histomorphometric analysis and scanning electron microscopy were performed after stent implantation. Our results showed that after 7 days, there was no difference in the neointimal area and percent area stenosis in ENDs compared with SMSs or BMSs. After 14 days, the neointima area and percent area stenosis in ENDs were markedly decreased than those in BMSs or SESs (P
ISSN:2314-6133
2314-6141
DOI:10.1155/2014/428619